Document is current
Any future updates will be listed below
-
Authors
Reiss, David J. https://orcid.org/0000-0001-5392-3034
Nakayama, Yumi https://orcid.org/0000-0003-1279-1519
Weng, Andrew P. https://orcid.org/0000-0001-7394-5425
Stokes, Matthew E.
Sehn, Laurie
Steidl, Christian https://orcid.org/0000-0001-9842-9750
Scott, David W. https://orcid.org/0000-0002-0435-5947
Huang, C. Chris https://orcid.org/0000-0002-1116-2756
Gandhi, Anita K.
-
Funding
Funding for this research was provided by:
Terry Fox Research Institute (1061, 1108, 1061, 1061, 1108)
- License Information
-
More Information
Article History
Received: 30 October 2023
Revised: 25 March 2024
Accepted: 28 March 2024
First Online: 4 April 2024
Competing interests
: DJR, YN, MES, CCH, and AKG are employees of, and have financial interest in Bristol Myers Squibb. CS has performed consultancy for Bayer and Eisai, and has received research funding from Epizyme and Trillium Therapeutics. DWS has performed consultancy for Abbvie, AstraZeneca, Incyte, and Veracyte and received research funding from Roche. He is an inventor on patents describing using gene expression to subtype aggressive B-cell lymphomas, including one licensed to NanoString Technologies. APW and LS have no competing interests to disclose.
